C-Path’s Transplant Therapeutics Consortium is pleased to announce the recent publication in *Transplantation* by William Fitzsimmons and Maarten Naesens, “Acute Rejection After Kidney Transplant—An Endpoint Not Predictive of Treatment Effect on Graft Survival.”

The article highlights the lack of consistent treatment effect of BPAR on graft survival and the work we are doing in TTC to improve upon the current efficacy failure endpoint. TTC values all transplant stakeholders’ perspectives in aligning on a path forward that is evidence-based and can be practically implemented.

Access the article, here:
[https://journals.lww.com/transplantjournal/Citation/9900/Acute_Rejection_After_Kidney_Transplant_An.466.aspx](https://journals.lww.com/transplantjournal/Citation/9900/Acute_Rejection_After_Kidney_Transplant_An.466.aspx)